DLB vs IMAX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: DLB is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DLB and IMAX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DLB and IMAX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Dolby Laboratories licenses audio and imaging technologies to device makers, content creators, and distributors, earning royalties each time its formats are embedded in hardware or content. Its flagship brands (Dolby Atmos for immersive audio and Dolby Vision for HDR imaging) sit inside televisions, smartphones, PCs, set-top boxes, sound systems, streaming platforms, cinemas, and increasingly automotive infotainment. The model is asset-light: Dolby invests heavily in R&D and standardization, then monetizes the resulting patents and trademarks at very high gross margins once a format reaches critical mass.

Full DLB guide

IMAX Corporation designs and markets premium large-format cinema systems and licenses proprietary technology that lets studios remaster films into the IMAX format. Rather than owning most theaters itself, IMAX runs an asset-light model: it sells or leases its projection and sound systems to exhibitor partners, then earns ongoing revenue tied to ticket sales through revenue-share and joint-venture arrangements. Its two reporting segments are Technology Products and Services (the systems, maintenance, and network operations) and Content Solutions (film remastering, distribution, and the growing slate of local-language titles). By 2025 the IMAX network spanned more than 1,700 theaters globally, larger than rival premium formats.

Full IMAX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DLB drivers: Atmos and Vision penetration; Automotive as a new surface.
• IMAX drivers: Record box office and premium share; Local-language content expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Dolby's revenue is concentrated in patent and technology licensing, so expiring patents and the need to keep introducing successful new formats are structural risks to long-term royalty streams. For IMAX, iMAX's results depend heavily on the theatrical film release calendar, which it does not control, so a weak slate of major titles in any period can pressure box office and revenue.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DLB if you believe its drivers more; IMAX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DLB and IMAX guides.

DLB. Dolby trades at a mid-20s trailing earnings multiple that falls to the mid-teens on forward estimates, reflecting expected fiscal 2026 EPS growth toward the ~$2.66-$2.81 GAAP range. The valuation embeds a steady, high-margin licensing franchise with a strong net-cash balance sheet rather than a rapid grower. The gap between trailing and forward multiples partly reflects licensing true-ups and cyclicality that make single-year comparisons uneven.

IMAX. As of February 2026, IMAX reported best-ever full-year 2025 revenue of about $410 million with a net income margin near 11%, and the stock traded around the high $30s for a market cap near $2.2 billion. The trailing price-to-earnings multiple of roughly 60x is high relative to the broader market, reflecting expectations for continued record box office and network growth. The 2026 guidance of about $1.4 billion in global box office and 160 to 175 installations frames the growth the valuation assumes.

Headline figures (approximate, July 2026): DLB shows revenue (fy2025) ~$1.35B, net income (fy2025) ~$255M, fy2026 revenue guidance ~$1.4B-$1.45B, market cap ~$5.9B; IMAX shows revenue (fy2025) ~$410 million (+16%), net income margin ~11%, adjusted ebitda margin ~45% (record), global imax box office (2025) ~$1.28 billion (record).

DLB and IMAX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DLB and IMAX exposure against your real portfolio. It is not an investment adviser.